OBJECTIVES: Generally, cost parameters used in partitioned survival model (PSM) are summarized as follows; (1) drug costs in pre-progression, (2) other costs in preprogression, (3) drug costs in post-progression, and (4) other costs in post-progression. The purpose of this study was to develop a method to estimate these cost parameters by using claims database from the perspective of the Japanese healthcare system. METHODS: Japan Medical Data Center (JMDC) Claims database was used to estimate these parameters. Receipt data of lung cancer patients was extracted by using ICD-10 code. The number of patients and total person-time was 10,883 and 119,409 person-month (Jan 2005 -Jan 2017), respectively. Cost data with binary variables which indicate the use of lung cancer drugs were converted to panel dataset. In this study, we considered eight lung cancer drugs. The month in which the lung cancer drug first appeared was taken as the treatment start month and the month in which it appeared last was assumed to be the treatment end month due to progression of disease. Panel data analysis was performed to estimate cost parameters in pre-progression and post-progression in each lung cancer drug. RESULTS: Average monthly drug costs for pre-progression ranged from JPY 46,149 to JPY 2,463,270. Drug costs for post-progression were estimated from JPY 130,876 to JPY 1,135,732. Other costs for pre-and post-progression ranged from JPY 108,450 to JPY 453,855, and from JPY 145,009 to JPY 456,490, respectively. CONCLUSIONS: Although there are several technical problems, claims database is considered to be useful data source in costeffectiveness analysis based on PSM. Further research is required on a method to identify occurrence of clinical event based on claim database.
PCN25 EVALUATING AVAILABILITY, PRICES AND AFFORDABILITY: CASE STUDY OF SELECTED ONCOLOGY AND INNOVATOR MEDICINES IN MALAYSIA
Wong SL, Ibrahim S, Kadir NA, Salleh SM Ministry of Health Malaysia, Petaling Jaya, Malaysia OBJECTIVES: High-priced medicines such as patented innovators and oncology items are great burden to healthcare budgets and barriers to treatment access worldwide. This study investigates availability, medicine price and affordability of selected oncology and on-patent medicines (medicines that still have patent protection) in Malaysia's public and private sectors. METHODS: This cross sectional study adapted the validated methodology developed by the World Health Organization/ Health Action International. Procurement and patient prices were collected from public and private facilities nationwide for a case study of four oncology and four on-patent medicines. Availability was reported as the percentage of medicine outlets with the medicine. For international comparison, median prices were compared against International Reference Price (IRP). Mark-up was calculated as the percentage of patient price to procurement price. Affordability was determined by the number of days' wages required for selected treatment courses. RESULTS: The average availability of the selected basket of oncology and on-patent medicines were 53.9% the most(30.8%), 15 out of 33 CAM on Breast cancer was Mind-body intervention. CONCLUSIONS: The study has found CAM for cancer patients has generally been on the rise. Interventions were biased in a specific category since Acupuncture and Chinese herbal medicines were studied much more than other CAM. Further researches need to be conducted in less studied CAM. Moreover, high quality evidences are needed for future study. Systematic review registration: PROSPERO CRD42018090318
PCN15 EVALUATING NSCLC TREATMENT OPTIONS USING REAL WORLD DATA: FINDINGS FROM AN ONCOLOGY SURVEY ACROSS EIGHT COUNTRIES
Takeno S 1 , Tanaka S 1 , Saijo N 1 , Nasuti P 2 1 IQVIA, Minato-ku, Tokyo, Japan, 2 IQVIA, London, UK OBJECTIVES: Non-small Cell Lung Cancer (NSCLC) has always been considered a disease of genomic alternations. Clinical data supports the hypothesis that the PD-1/PDL1 interaction is an important regulator in tumour immune tolerance and tumour growth in NSCLC. Although immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) or its ligand, PD-L1, have gained momentum in the treatment of NSCLC, there is a lack of published data that compares current real-world testing rates and PD-1 antibodies use across 8 countries. METHODS: This study used an IQVIA oncology cross-sectional survey collecting anonymized patientlevel data in France, Germany, Spain, Italy, UK, China, Korea and Japan between January -December 2017. RESULTS: Of the 17,886 surveyed NSCLC patients, 32.3% were tested for PD-L1 expression across 8 countries. Specifically, the ratio of each country was 35. 4% in Japan, 35.5% in Korea, 2.4% in China, 34.2% in France, 67.8% in Germany, 54.7% in Great Britain, 21.6% in Italy, and 38.3% in Spain. In addition, 61.7% of NSCLC metastatic patients with PDL1 expression were prescribed anti-PD-1 and anti-PDL1 antibodies: 52.1% Japan, 26.7% Korea, China 25.0%, 63.5% Germany, 61.1% Spain, 48.3% France, 74.1% Great Britain, 71.2% Italy. Regarding the patients who were prescribed anti-PD-1 and anti-PDL1 antibodies, 62.4% of them were prescribed Pembrolizumab, 36.0% Nivolumab, 1.1% Atezolizumab, 0.3% Avelumab and 0.3% Durvalumab. CONCLUSIONS: This study shows a large difference across 8 countries in regards to PD-1 expression testing and use of anti-PD-1 and anti-PDL-1 antibodies. The precise role of PD-L1 positivity remains to be defined within this patient segment as testing rates for expression remain really low or non-existent in some countries. Further analysis will be required to understand the time to PD-1/ PDL1 expression testing and to understand differences in the typical patient profile of patients treated with standard care vs anti-PD-1/PD-L1 treatments.
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PCN18 BUDGET IMPACT ANALYSIS OF REGORAFENIB IN THE THIRD-LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER
Zhu S 1 , Liu J 1 , Sun W 2 , Xuan J 3 1 Shanghai Centennial Scientific Co., Ltd, Shanghai, China, 2 Bayer Healthcare Co., Ltd., Beijing, China, Guangzhou, China OBJECTIVES: To evaluate the impact of Regorafenib in the third-line treatment of patients with metastatic colorectal cancer (mCRC) on the insurance budget when incorporated in the reimbursement list. METHODS: Building a budget impact model to assess the impact of Stivarga on health insurance expenditure over three years after the inclusion of Regorafenib in China's national reimbursement drug list (NRDL). In the model, the disease incidence data were abstracted from literatures, disease diagnosis rate, treatment rate and direct medical costs were obtained from an expert opinion survey. Other data such as market share of third-line treatments were derived from market research. RESULTS: Total annual reimbursement expenditure in 1, 2, and 3 years following the NRDL inclusion was decreased by 90 million RMB, 67 million RMB and 47 million RMB respectively. The cost reduction is mainly due to the potential elimination of the current non evidence-based salvage therapies. Sensitivity analysis was carried out on the parameters of monthly treatment cost, market shares and reimbursement ratio. The sensitivity analysis did not change the direction of the results indicating that the basic analysis results are robust. CONCLUSIONS: The analysis estimated that, following the inclusion of Regorafenib in China's NRDL for third-line treatment of patients with metastatic colorectal cancer (mCRC), the overall health care expenditures were reduced due to the potential elimination of the current non evidence-based salvage therapies.
PCN21
COST-EFFECTIVENESS OF DURVALUMAB AFTER CHEMORADIATION IN STAGE III NON-SMALL CELL LUNG CANCER (NSCLC)
Criss SD 1 , Mooradian MJ 2 , Lumish MA 2 , Reynolds KL 2 , Kong CY 1 1 Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA, USA, 2 Oncology, Massachusetts General Hospital, Boston, MA, USA OBJECTIVES: In early 2018, durvalumab became the first immunotherapy to be approved for adjuvant treatment of patients with stage III unresectable NSCLC whose cancer has not progressed after definitive chemoradiation. We evaluate the cost-effectiveness and potential budget impact of durvalumab as a consolidation therapy in the context of the U.S. health care system. METHODS: A microsimulation model was developed to compare three post-chemoradiation treatment strategies: (1) all patients receive no additional treatment until progression, (2) nonsquamous patients receive consolidation pemetrexed for four cycles or until progression and squamous patients receive no treatment, and (3) all patients receive consolidation durvalumab for one year or until progression. Budget impact was calculated by applying the proportion of NSCLC patients who are diagnosed in stage III and receive chemoradiation to the projected number of annual cases for 2018-2022, to find total eligible patients, then multiplying by mean treatment cost. Results are reported in 2017 U.S. dollars. RESULTS: Administering no additional treatment after chemoradiation resulted in a mean cost of $190,270 and mean effect of 1.25 quality-adjusted life-years (QALYs). Consolidation
